Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Tango Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FIRST CLINICAL DATA FROM PRMT5/RAS(ON) COMBINATION TRIAL TO BE PRE SENTED IN 2026 CASH POSITION OF $380 MILLION AS OF MARCH 31, 2026, WITH RUNWAY INTO 2028 BEYOND ANTICIPATED KEY DATA INFLECTION POINTS BOSTON, MAY 13, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED BUSINESS HIGHLIGHTS. WE CONTINUE TO WORK DILIGENTLY TO ADVANCE VOPIMETOSTAT TOWARDS PIVOTAL DEVELOPMENT IN PANCREATIC CANCER AND REMAIN HIGHLY ENCOURAGED BY THE POTENTIAL OF THE ONGOING STUDY OF VOPIMETOSTAT IN COMBINATION WITH RAS(ON) INHIBITORS, SAID MALTE PETERS, M.D.

TANGO THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS

BOSTON, MAY 04, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), TODAY ANNOUNCED THAT EFFECTIVE MAY 1, 2026, THE COMPENSATION COMMITTEE OF TANGO THERAPEUTICS' BOARD OF DIRECTORS GRANTED (I) A NON-QUALIFIED STOCK OPTION TO PURCHASE AN AGGREGATE OF 240,000 SHARES OF ITS COMMON STOCK AND 40,000 RESTRICTED STOCK UNITS (RSUS) TO MATTHEW GALL, THE COMPANY'S CHIEF FINANCIAL OFFICER AND (II) A NON-QUALIFIED STOCK OPTION TO PURCHASE AN AGGREGATE OF 199,650 SHARES OF ITS COMMON STOCK AND 33,250 RSUS TO A NEW EMPLOYEE, UNDER TANGO THERAPEUTICS' 2023 INDUCEMENT PLAN.

TANGO THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

- MATTHEW GALL APPOINTED CHIEF FINANCIAL OFFICER - - ADDITIONAL KEY APPOINTMENTS ADD EXPERTISE IN CLINICAL OPERATIONS, CORPORATE STRATEGY AND PROJECT LEADERSHIP -

TANGO THERAPEUTICS ANNOUNCES LEADERSHIP APPOINTMENTS TO ACCELERATE LATE-STAGE DEVELOPMENT OF VOPIMETOSTAT

BOSTON, JAN. 08, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES TODAY ANNOUNCED THE RETIREMENT OF ITS CHIEF EXECUTIVE OFFICER, DR. BARBARA WEBER, EFFECTIVE TODAY JANUARY 8, 2026. DR. WEBER, THE COMPANY'S FOUNDING CEO, WILL BECOME EXECUTIVE CHAIR FOR 2026 AND THEN SERVE AS NON-EXECUTIVE CHAIR STARTING IN 2027. SHE IS SUCCEEDED BY DR. MALTE PETERS, A DISTINGUISHED LEADER WITH EXTENSIVE CLINICAL DEVELOPMENT AND LEADERSHIP EXPERIENCE AND WHO HAS SERVED ON THE TANGO BOARD OF DIRECTORS SINCE 2018, WHO WILL DRIVE THE NEXT PHASE OF COMPANY GROWTH.

TANGO THERAPEUTICS ANNOUNCES CEO TRANSITION: BARBARA WEBER TO RETIRE, MALTE PETERS APPOINTED SUCCESSOR

BOSTON, JAN. 05, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY ANNOUNCED THE APPOINTMENT OF MR. SUNG LEE TO THE BOARD OF DIRECTORS. MR. LEE HAS OVER 20 YEARS OF EXPERIENCE IN FINANCE LEADERSHIP IN THE BIOPHARMACEUTICAL AND TECHNOLOGY INDUSTRIES.

TANGO THERAPEUTICS APPOINTS SUNG LEE TO BOARD OF DIRECTORS

BOSTON, DEC. 17, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), TODAY ANNOUNCED THAT BARBARA WEBER, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER OF TANGO THERAPEUTICS, IS SCHEDULED TO DELIVER A CORPORATE PRESENTATION AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ON WEDNESDAY, JANUARY 14, 2026 AT 9:45AM PST/12:45PM EST.

TANGO THERAPEUTICS TO PARTICIPATE IN 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

BOSTON, NOV. 26, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), TODAY ANNOUNCED THAT ADAM CRYSTAL, M.D., PH.D., PRESIDENT OF RESEARCH & DEVELOPMENT AT TANGO THERAPEUTICS, IS SCHEDULED TO PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE ON WEDNESDAY, DECEMBER 3 AT 1:30PM ET.

TANGO THERAPEUTICS TO PARTICIPATE IN THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

- DATA UPDATE FROM VOPIMETOSTAT (TNG462) SHOWED 2L MTAP-DEL PANCREATIC CANCER MEDIAN PROGRESSION FREE SURVIVAL (MPFS) 7. 2 MONTHS- - COMBINATION STUDIES WITH RAS(ON) INHIBITORS ONGOING, DATA ANTICIPATED 2026 - - 49% ORR AND MPFS 9. 1 MONTHS IN HISTOLOGY SELECTIVE COHORT OF MULTIPLE LATE LINE, DIFFICULT TO TREAT CANCERS PROVIDE FURTHER EVIDENCE OF STRONG ACTIVITY - - $225 MILLION IN GROSS PROCEEDS FROM OCTOBER 2025 FINANCING EXTENDS CASH RUNWAY INTO 2028 - BOSTON, NOV.

TANGO THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS

TANGO THERAPEUTICS, INC. (NASDAQ:TNGX ) DISCUSSES POSITIVE CLINICAL DATA AND DEVELOPMENT PLANS FOR VOPIMETOSTAT IN MTAP-DELETED CANCERS OCTOBER 23, 2025 8:30 AM EDT COMPANY PARTICIPANTS ELIZABETH HICKIN - VP OF IR & CORPORATE COMMUNICATIONS BARBARA WEBER - PRESIDENT, CEO & DIRECTOR ADAM CRYSTAL - PRESIDENT OF RESEARCH & DEVELOPMENT CONFERENCE CALL PARTICIPANTS ERIC SCHMIDT - CANTOR FITZGERALD & CO., RESEARCH DIVISION MICHAEL SCHMIDT - GUGGENHEIM SECURITIES, LLC, RESEARCH DIVISION MAURICE RAYCROFT - JEFFERIES LLC, RESEARCH DIVISION PETER LAWSON - BARCLAYS BANK PLC, RESEARCH DIVISION ROBERT DRISCOLL - WEDBUSH SECURITIES INC., RESEARCH DIVISION KELSEY GOODWIN - PIPER SANDLER & CO., RESEARCH DIVISION YUAN ZHI - B. RILEY SECURITIES, INC., RESEARCH DIVISION PRESENTATION OPERATOR GOOD DAY.

TANGO THERAPEUTICS, INC. (TNGX) DISCUSSES POSITIVE CLINICAL DATA AND DEVELOPMENT PLANS FOR VOPIMETOSTAT IN MTAP-DELETED CANCERS TRANSCRIPT

FINANCING PARTICIPANTS INCLUDE FARALLON CAPITAL MANAGEMENT, TCGX, BALYASNY ASSET MANAGEMENT, WOODLINE PARTNERS LP, NEXTECH, INVUS, ADAGE CAPITAL MANAGEMENT LP, BOXER CAPITAL MANAGEMENT, LOGOS CAPITAL, NANTAHALA CAPITAL, ACCOUNTS ADVISED BY T. ROWE PRICE INVESTMENT MANAGEMENT, INC., AND A LARGE INSTITUTIONAL INVESTOR FINANCING PARTICIPANTS INCLUDE FARALLON CAPITAL MANAGEMENT, TCGX, BALYASNY ASSET MANAGEMENT, WOODLINE PARTNERS LP, NEXTECH, INVUS, ADAGE CAPITAL MANAGEMENT LP, BOXER CAPITAL MANAGEMENT, LOGOS CAPITAL, NANTAHALA CAPITAL, ACCOUNTS ADVISED BY T. ROWE PRICE INVESTMENT MANAGEMENT, INC., AND A LARGE INSTITUTIONAL INVESTOR

Tango Therapeutics, Inc.

TNGX

Price

Financial Reports

No items found.

Press Releases

Tango Therapeutics, Inc.

TNGX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TNGX